Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

Bryn Golesworthy1,2†, Yifan Wang1,2,3†, Amanda Tanti1,2, Alain Pacis2,4, Joan Miguel Romero1,2, Adeline Cuglia1,2, Celine Domecq1,2, Guillaume Bourdeix1,2, Robert E. Denroche5, Gun Ho Jang5, Robert C. Grant5, Ayelet Borgida6, Barbara T. Grünwald7, Anna Dodd7, Julie M. Wilson5, Guillaume Bourque4,8, Grainne M. O’Kane5,7, Sandra E. Fischer5,9, Chelsea Maedler Kron1,10, Pierre-Olivier Fiset1,10, Atilia Omeroglu1,10, William D. Foulkes1,8, Steven Gallinger5,6,7, Marie-Christine Guiot2,10, Zu-Hua Gao1,10 and George Zogopoulos1,2,3*

1 The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2 The Rosalind and Morris Goodman Cancer Institute of McGill University, Montreal, QC, Canada, 3 The Department of Surgery, McGill University, Montreal, QC, Canada, 4 The McGill Genome Center and Canadian Centre for Computational Genomics (C3G), Montreal, QC, Canada, 5 The Ontario Institute for Cancer Research, Toronto, ON, Canada, 6 The Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada, 7 The Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, 8 The Department of Human Genetics, McGill University, Montreal, QC, Canada, 9 The Division of Pathology, University Health Network, Toronto, ON, Canada, 10 The Department of Pathology, McGill University, Montreal, QC, Canada

The immune contexture of pancreatic ductal adenocarcinoma (PDAC) is generally immunosuppressive. A role for immune checkpoint inhibitors (ICIs) in PDAC has only been demonstrated for the rare and hypermutated mismatch repair (MMR) deficient (MMR-d) subtype. Homologous recombination repair (HR) deficient (HR-d) PDAC is more prevalent and may encompass up to 20% of PDAC. Its genomic instability may promote a T-cell mediated anti-tumor response with therapeutic sensitivity to ICIs. To investigate the immunogenicity of HR-d PDAC, we used multiplex immunohistochemistry (IHC) to compare the density and spatial distribution of CD8+ cytotoxic T-cells, FOXP3+ regulatory T-cells (Tregs), and CD68+ tumor-associated macrophages (TAMs) in HR-d versus HR/MMR-intact PDAC. We also evaluated the IHC positivity of programmed death-ligand 1 (PD-L1) across the subgroups. 192 tumors were evaluated and classified as HR/MMR-intact (n=166), HR-d (n=25) or MMR-d (n=1) based on germline testing and tumor molecular hallmarks. Intra-tumoral CD8+ T-cell infiltration was higher in HR-d versus HR/MMR-intact PDAC (p<0.0001), while CD8+ T-cell densities in the peri-tumoral and stromal regions were similar in both groups. HR-d PDAC also displayed increased intra-tumoral FOXP3+ Tregs (p=0.049) and had a higher CD8+:FOXP3+ ratio (p=0.023). CD68+ TAM expression was similar in HR-d and HR/MMR-intact PDAC. Finally, 6 of the 25 HR-d cases showed a PD-L1 Combined Positive Score of >=1, whereas none of the HR/MMR-intact cases met this threshold (p<0.00001). These results provide...
INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer death worldwide and its incidence is rising yearly (1). It is one of the most lethal malignancies, with a 5-year survival rate of less than 10% (1). Nearly 80% of patients are diagnosed with incurable locally advanced or metastatic disease and are treated with systemic chemotherapy (2). However, the effectiveness of empiric chemotherapeutic regimens, such as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) and gemcitabine plus nab-paclitaxel, remains poor (2). The 20% of patients who undergo curative-intent resection and receive adjuvant therapy reach a median overall survival of only 22.8 to 54.4 months, which highlights the systemic behavior of PDAC even at its earliest stage (3–5).

While empiric chemotherapy regimens remain the backbone of systemic treatment for PDAC, these treatment strategies have not led to marked improvements in survival [2]. Thus, guided by biomarker-driven treatment breakthroughs in other difficult-to-treat cancers and facilitated by the identification of PDAC molecular subtypes, precision medicine and immunotherapy strategies have emerged. The most characterized molecular PDAC subtypes are based on 1) genomic tumor alterations driven either by germline predisposition or somatic oncogenic aberrations and 2) transcriptomic expression patterns (6). Associations of these subtypes with PDAC progression and treatment responses have demonstrated their potential clinical value (7–9).

Homologous recombination repair (HR) deficiency (HR-d) PDAC is an actionable molecular subtype. It is primarily driven by germline mutations in BRCA2, BRCA1 and PALB2, which are present in 5-10% of incident PDAC cases (2, 10–13). In addition, 7-10% of PDAC cases without germline mutations in HR-associated genes harbor molecular hallmarks of HR-d driven by somatic or epigenetic events (14). HR-d PDAC is sensitive to platinum-based cytotoxic regimens and poly(ADP-ribose) polymerase (PARP) inhibitors, which exploit the intrinsic deficiency of HR-d tumor cells to repair DNA double strand breaks with high-fidelity (15). In addition, the genomic instability of HR-d tumors, characterized by specific genomic alterations that include deletions with flanking microhomology and the COSMIC Signature 3 pattern of base-substitution mutations, may lead to increased neoantigens and a T cell-mediated anti-tumor response with therapeutic sensitivity to immune checkpoint inhibitors (ICIs) (16, 17). Durable treatment responses to ICIs have been demonstrated in cancers with T cell-inflamed phenotypes, but the ability of HR-d PDAC to induce anti-tumor immunity has not been established (18). Moreover, the PDAC tumor microenvironment is generally immunosuppressive and a role for ICIs in PDAC has only been demonstrated for the rare and hypermutated mismatch repair (MMR) deficient (MMR-d) subtype, which exhibits inherent immunogenicity (19, 20). Thus, to assess the potential actionability of HR-d PDAC using ICIs, we characterized the spatial distribution of immune cells relative to tumor cells in HR-d versus HR/MMR-intact PDAC.

MATERIALS AND METHODOLOGY

Patient Cohorts

Tumor specimens from patients with pathological diagnoses of PDAC from two case series were evaluated. The first series included 141 PDAC cases from the Quebec Pancreas Cancer Study [QPCS, NCT04104230 (21)]. This series consisted of 130 consecutive patients enrolled in the QPCS between April 2012 and September 2018, with available primary resected PDAC specimens for construction of a tissue microarray (TMA). To compensate for the lower incidence of HR-d and MMR-d compared to HR/MMR-intact PDAC, we also included cases with germline mutations in HR or MMR genes (n=11) that were enrolled in the QPCS following construction of the TMA. These included primary (n=8) and metastatic (n=3) PDAC specimens from cases enrolled between October 2018 and December 2020. The second series consisted of 115 cases from the PanCuRx Translational Research Initiative, which were represented on a previously constructed TMA (22). Patient demographics, clinical characteristics and survival outcomes for both series were extracted from prospectively maintained study databases. Overall survival was calculated from the date of radiological diagnosis until death or censor date. Clinical staging was based on the 8th edition of the American Joint Committee on Cancer.

Construction of Tissue Microarrays

TMAs for the QPCS cases were created using an automated tissue microarrayer (TMA Grand Master, 3DHistech, RRID: SCR_021257). Representative tumor regions were identified on hematoxylin and eosin (H&E) stained slides by a board-certified pathologist (A.O., Z.H.G.) and marked on its corresponding formalin-fixed and paraffin-embedded (FFPE) block. Each case (n=130) was represented on a TMA by three 1.5-mm tumor cores. The PanCuRx TMA was previously constructed and included 115 cases that were each represented by at least two 1.5-mm cores (22).

Immunostaining and Spatial Analysis of Tumor Infiltrating Immune Cells

TMA and individual patient blocks were cut at a 4-micrometer (μm) thickness for immunohistochemistry (IHC). Multiplex immunohistochemical evidence for intra-tumoral CD8+ T-cell enrichment and PD-L1 positivity in HR-d PDAC, suggesting that HR-d PDAC may be amenable to ICI treatment strategies.

Keywords: pancreatic cancer, tumor microenvironment, T-cell inflammation, immunotherapy, PD-L1
These cases were classified as intra-tumoral if they were located within 10 μm from the edge of a tumor cell (Figure 1A). Immune cells were considered peri-tumoral if they were located between 10 μm and 50 μm from the tumor cell cluster perimeter. Immune cells that were more than 50 μm away from a tumor cell cluster perimeter were categorized as stromal. The CD8+FOXp3+ ratio was calculated by dividing the total number of CD8+ cytotoxic T-lymphocytes by the total number of FOXP3+ regulatory T-lymphocytes (Tregs) in each core, and averaging across tumor replicates. The Combined Positive Score (CPS) was calculated for each core as previously described (23) and averaged across tumor replicates. A CPS of ≥1 was considered positive. The HALO analysis for PD-L1 staining was validated with manual scoring by a board-certified pathologist (M.C.G.).

Identification of HR-d and MMR-d Cases

Across the two series, 192 cases (QPCS n=114; PanCuRx n=78) were evaluable (Table 1 and Supplementary Table 1). These cases were classified into HR/MMR-intact, HR-d or MMR-d subgroups and their immune tumor microenvironment was compared (Supplementary Tables 2, 3). To identify HR-d cases in the QPCS series, we performed germline testing using lymphocyte DNA for BRCA1, BRCA2, and PALB2 mutations. There were 52 cases previously tested by whole genome sequencing (WGS, n=11), whole exome sequencing (WES, n=1), or targeted sequencing using genes panels that included BRCA1, BRCA2, and PALB2 (n=40, Supplementary Table 4) (13, 24, 25). The remaining 62 cases that had not undergone germline genetic testing were evaluated using the INVITAE Multi-Cancer gene panel (Supplementary Table 4). Germline mutations for the PanCuRx series were abstracted from previously reported WGS of lymphocyte DNA (22).

For cases that had undergone tumor whole genome sequencing (8, 17, 22), we calculated the HRDetect score using previously described methodology (26). Assignment of cases to the HR-d subgroup was based on the presence of a germline BRCA1, BRCA2 or PALB2 mutation and, if available, an HRDetect score of ≥0.9. If an HRDetect score was unavailable, cases with germline mutations were kept in the HR-d subgroup. Cases that carried a germline mutation, but did not meet the HRDetect threshold, were considered HR-intact. An HRDetect score of >0.7 for a low tumor cellularity case (303.001) was accepted to signify HD-d. In the absence of a germline HR-gene mutation, cases that had an HRDetect score >0.9 and evidence of somatic HR-gene inactivation were classified as HR-d.

We surveyed the QPCS and PanCuRx case series for germline MMR-gene mutations to identify potential MMR-d cases (Supplementary Tables 2, 3). However, assignment to the MMR-d subgroup was based on IHC for MMR protein deficiency (i.e., MLH1, MSH2, MSH6, PMS2) or an MSIsensor score ≥20 (https://github.com/niu-lab/msisensor2). For the QPCS series, IHC for MLH1 (G168-15, Biocare Medical, RRID: AB_1059376), MSH2 (G219-1129, Cell Marque, RRID: AB_1160591), MSH6 (EP3945, Abcam, RRID: AB_2144959) and PMS2 (EP3947, Cell Marque) was performed using a BenchMark ULTRA IHC Staining Module (Roche Diagnostics) with the OptiView DAB IHC Detection Kit. IHC staining was analyzed using the ImageScope software. Cases were considered MMR-intact if tumor cells displayed nuclear staining of all 4 MMR proteins. Cases were classified as MMR-d if tumor cells had complete loss of nuclear staining in one or more MMR proteins, with retained nuclear staining in adjacent stroma. Absence of MMR protein expression on a TMA core was confirmed by staining a whole section slide. MMR-d classification for the PanCuRx case series was based on previously reported IHC for MLH1, MSH2, MSH6 and PMS2 or MSIsensor scores (19, 22). Cases were assigned to the HR/MMR-intact subgroup if they did not meet criteria for HR-d or MMR-d subclassification or if they could not be evaluated for tumor molecular hallmarks due to biospecimen availability.

Statistical Analyses

All statistical analyses were performed using R Software (version 4.0.4, R Foundation for Statistical Computing). Continuous variables were expressed as mean ± standard deviation (SD), and differences were compared using the Wilcoxon test. Fisher’s Exact Test was used to compare the proportion of cases in the HR/MMR-intact versus HR-d groups meeting the PD-L1 CPS threshold of ≥1. Overall survival was estimated using the
Kaplan–Meier method and compared between groups using a log-rank test.

**Study Approval**

All participants provided written informed consent. The study was conducted in accordance with the principles of the Declaration of Helsinki. The McGill University and the McGill University Health Centre (MUHC) Institutional Review Boards (#A02-M118-11A, #2018-3171, #2018-4139) approved the QPCS study, and the Institutional Review Board of the University Health Network (#15-9596) provided approval for the PanCuRx case series.
RESULTS

Clinical Characteristics

Across the QPCS and PanCuRx case series, 192 PDAC cases were characterized, which included 166, 25, and 1 HR/MMR-intact, HR-d, and MMR-d cases, respectively (Table 1). The germline mutations and tumor genomic features of the HR-d and MMR-d cases are summarized in Table 2, and their clinical characteristics at tumor biospecimen acquisitions are detailed in Table 3. The HR-d group demonstrated a longer median overall survival (OS; 29.1 months versus 19.9 months, p=0.0073; Supplementary Figure 1). Notably, the HR-d group included a greater number of patients diagnosed with stage III/IV disease compared to the HR/MMR-intact group (52.0% versus 4.2%, p<0.0001).

Increased Intra-tumoral Density of CD8+ T-cells and FOXP3+ Tregs in HR-d PDAC

HR-d tumors had a higher CD8+ T-cell intra-tumoral density compared to the HR/MMR-intact group (131.1 ± 154.9 cells/mm² versus 40.5 ± 50.9 cells/mm², p<0.0001; Figure 1). However, there was no difference in CD8+ T-cell infiltration in the peri-tumoral or stromal regions between the two groups. The CD8+ T-cell landscape for the MMR-d case is shown in parallel as a reference for a PDAC microenvironment responsive to immunotherapy. Following resection of the primary and adjuvant therapy with gemcitabine/capecitabine, this patient (750.001) developed a mesenteric recurrence, which responded to pembrolizumab (Supplementary Figure 2).

We subsequently evaluated the landscape of FOXP3+ Tregs and CD68+ tumor-associated macrophages (TAMs) in HR/MMR-intact versus HR-d tumors (Figure 2). FOXP3+ Tregs density was higher in the intra-tumoral region of HR-d versus HR/MMR-intact tumors (25.5 ± 27.3 cells/mm² versus 13.6 ± 13.4 cells/mm², p=0.049), while there was no difference in FOXP3+ staining in the peri-tumoral or stromal regions between the two groups. Moreover, the ratio of CD8+ to FOXP3+ cells was higher in HR-d versus HR/MMR-intact cases (23.9 ± 52.7 versus 9.8 ± 23.8, p=0.023). Similarly, the CD8+ to FOXP3+ ratio in the MMR-d tumor was also elevated. CD68+ TAM population densities were comparable across the three spatial compartments in HR-d and HR/MMR-intact PDAC.

Increased PD-L1 Expression in HR-d PDAC

We observed higher PD-L1 expression in the HR-d versus the HR/MMR-intact group (5.1 ± 11.9 versus 0.03 ± 0.1, p=0.0025). Six of the 25 HR-d tumors met the PD-L1 Combined Positive Score (CPS) threshold of ≥1, whereas none of the 163 evaluable HR/MMR-intact tumors reached the positivity threshold (p<0.0001; Figures 3A, B). The 6 HR-d cases with a CPS score ≥1 consisted of 4 cases with treatment-naïve primary PDAC biopsies (1024.001, 1183.001, 1235.001, 1337.001) and 2 metastatic biopsies (543.001, liver metastasis; 1099.001, peritoneal metastasis). Case 543.001 was treatment naïve at the time of biopsy, whereas case 1099.001 had undergone a course of neoadjuvant FOLFIRINOX for stage III disease. The biopsied metastatic peritoneal nodule was identified at the time of surgical exploration and the curative-intent resection was aborted following the intra-operative finding of metastatic disease. Importantly, the MMR-d case with treatment sensitivity to pembrolizumab also met the CPS threshold (Figure 3B, Supplementary Figure 2).

DISCUSSION

Genomic and transcriptomic profiling of PDAC has identified distinct molecular subclasses, such as HR-d (6). These advances have led to opportunities for targeted therapies and treatment stratification according to subclass assignment. Treatment responses to platinum-based therapies and PARP inhibitors have been demonstrated for HR-d PDAC (14, 27, 28). However, these therapies rarely lead to complete tumor responses and their durability is limited (17, 27). Therefore, there remains a clinical need to improve the current treatment strategies for HR-d PDAC. To this end, the genomic instability associated with HR-d PDAC may result in a tumor microenvironment amenable to ICI therapies. In the present...
study, we show increased intra-tumoral CD8+ T-lymphocyte infiltration and PD-L1 positivity by immunohistochemistry, corroborating previously reported transcriptomic evidence for T-cell inflammation in HR-d PDAC (22, 29). Although evaluation of the composition of cytotoxic, memory and exhausted intra-tumoral CD8+ T-lymphocyte populations in HR-d is subject to further investigation, there is evidence that infiltrating CD8+ T-lymphocytes are activated in HR-d. Indeed, Connor et al. showed that the cytolytic activity of infiltrating CD8+ T-lymphocytes, as measured by expression of granzyme A and perforin, and expression of co-regulatory genes, including cytotoxic T-lymphocyte antigen 4, programmed cell death 1 and indolamine 2,3-dioxygenase 1, was increased in HR-d and MMR-d PDAC (22). Moreover, these gene expression changes correlated with higher frequency of somatic mutations and tumor-specific neoantigens.

ICI therapies promote an anti-tumor immune response by disrupting signals that inhibit T-cell cytolytic activity (30). Cancers that exhibit immunogenicity, such as melanoma, have robust responses to ICI regimens with striking tumor regression and long-term survival (30). CD8+T-cell tumor infiltration has been associated with such potent and durable ICI treatment responses (31). Importantly, the proximity of cytolytic CD8 T-cells to tumor cell bed is predictive of ICI efficacy (32). However, while CD8+T-lymphocytes are adjacent to tumor cells in the microenvironment of melanoma tumors, the CD8+T-lymphocyte infiltrate in PDAC

| Subgroup Classification | ID  | Germline Mutation | Somatic (Tumor) Alteration | HRDetect Score † | MSISensor Score † | MMR IHC         |
|-------------------------|-----|-------------------|---------------------------|----------------|----------------|----------------|
| HR-d                    | 348.001 | BRCA1 | c.2681_2682delAA | BRCA1 LOH          | >0.999          | 1.76           | Intact |
|                         | 1048.001 | BRCA1 | c.1018C>T          | BRCA1 deletion (chr17:41249032-56381777) | >0.999          | 2.05           | Intact |
|                         | PCSI_0476 | BRCA1 | c.5319dupC         | BRCA2 c.1794_1798del | >0.999          | 2.17           | Intact |
|                         | 70.001   | BRCA2 | c.3398del65        | BRCA2 c.2050C>T     | >0.999          | 1.62           | Intact |
|                         | 99.001   | BRCA2 | c.4691dupC         | BRCA2 c.3545delTT   | >0.999          | 2.05           | Intact |
|                         | 392.001  | BRCA2 | c.8677C>T          | BRCA2 c.3897delC    | >0.999          | 0.17           | Intact |
|                         | 543.001  | BRCA2 | c.8297delC         | BRCA2 LOH           | >0.999          | 0.73           | Intact |
|                         | 1024.001 | BRCA2 | c.1805_1806insA    | BRCA2 LOH           | >0.999          | 0.73           | Intact |
|                         | 1183.001 | BRCA2 | c.4284dup          | BRCA2 LOH           | >0.999          | 1.46           | Intact |
|                         | 1195.001 | BRCA2 | c.3170_3174del     | BRCA2 LOH           | >0.999          | 1.14           | Intact |
|                         | 1227.001 | BRCA2 | c.8537_8538del     | BRCA2 LOH           | >0.999          | 0.96           | Intact |
|                         | 1235.001 | BRCA2 | c.3170_3174del     | BRCA2 LOH           | >0.999          | 1.14           | Intact |
|                         | 1337.001 | BRCA2 | c.6275_6276del     | BRCA2 LOH           | >0.999          | 2.05           | Intact |
|                         | PCSI_0017 | BRCA2 | c.5946delT         | BRCA2 LOH           | >0.999          | 2.44           | Intact |
|                         | PCSI_0048 | BRCA2 | c.5946delT         | BRCA2 LOH           | >0.999          | 0.96           | Intact |
|                         | PCSI_0075   | BRCA2 | c.5718_5719del     | BRCA2 c.6579A>G     | >0.999          | 1.46           | Intact |
|                         | PCSI_0142   | BRCA2 | c.9435_9436delGT   | BRCA2 LOH           | >0.999          | 1.74           | Intact |
|                         | PCSI_0176   | BRCA2 | c.3167_3170delAAA | BRCA2 LOH           | >0.999          | 1.14           | Intact |
|                         | PCSI_0218   | BRCA2 | c.8910G>A          | BRCA2 c.8910G>A     | >0.999          | 0.73           | Intact |
|                         | PCSI_0472   | BRCA2 | c.5718_5719del     | BRCA2 c.3169+1G>T   | >0.999          | 2.32           | Intact |
|                         | PCSI_0477   | BRCA2 | c.9097dupA         | BRCA2 LOH           | >0.999          | 1.69           | Intact |
|                         | PCSI_0492   | BRCA2 | c.4003G>T          | BRCA2 LOH           | >0.999          | 1.69           | Intact |
|                         | 303.001    | PALB2 | c.2323C>T          | PALB2 c.2174C>G     | 0.742 §         | 1.36           | Intact |
|                         | 1099.001   | PALB2 | Deletion           | PALB2 Deletion      |                 |                | Intact |
| MMR-d                   | 750.001    | MSH2 | c.942+3A>T        | MSH2 & MSH6         | Intact |

¶ Somatic alterations were ascertained by whole genome sequencing.
† Shown are available results for cases with tumor whole genome sequencing.
* Patient-derived tumor xenograft tissue was used for whole genome sequencing when the patient tumor sample was insufficient.
§ Low tumor cellularity following laser microdissection (30.1%), which may have resulted in uncalled structural events and an HRDetect score of 0.742.
- Indicates no germline mutation identified.
LOH, loss of heterozygosity. MMR IHC, immunohistochemistry for mismatch repair proteins.
n/a Indicates insufficient tissue for immunohistochemistry.
is primarily restricted to the stroma (33). Despite such observations suggesting that PDAC does not generally evoke an anti-tumor immune response, genomic and transcriptomic characterization of PDAC and its microenvironment has alluded to the existence of PDAC subclasses harboring immunogenicity (34, 35). The subclass prototype for PDAC with immunogenicity and responsiveness to ICIs is MMR-d, which exhibits elevated levels of tumor mutation burden (TMB) and tumor infiltrating CD8 T-lymphocytes compared to MMR-intact PDAC (19, 20, 36). Similarly, if the genomic instability that underlies HR-d PDAC

**TABLE 3** | Clinical characteristics of the HR-d and MMR-d cases at tissue acquisition.

| Subgroup Classification | ID     | Age at Diagnosis (years) | Sex | Stage | Chemotherapy Prior to Tissue Acquisition | Radiation Therapy Prior to Tissue Acquisition | Tissue Acquisition Procedure | Tissue Acquired |
|-------------------------|--------|--------------------------|-----|-------|------------------------------------------|----------------------------------------------|-----------------------------|-----------------|
| HR-d                    | 348.001| 77                       | M   | II    | No                                       | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | 1048.001| 64                       | M   | IV    | No                                       | No                                           | Percutaneous Biopsy         | Primary Tumor    |
|                         | PCSI_0476| 42                       | M   | IIA   | FFX                                      | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | 70.001 | 47                       | M   | IV    | FFX                                      | No                                           | Distal pancreatectomy + splenectomy + RFA of liver metastases | Primary Tumor    |
|                         | 99.001 | 46                       | M   | II    | FFX, GC                                  | Yes                                          | Pancreaticoduodenectomy + PV resection + SMA resection | Primary Tumor    |
|                         | 392.001| 61                       | F   | II    | No                                       | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | 543.001| 75                       | M   | IV    | No                                       | No                                           | Percutaneous Biopsy         | Primary Liver Metastasis |
|                         | 908.001| 53                       | F   | III   | FFX                                      | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | 1024.001| 70                       | M   | IV    | No                                       | No                                           | Percutaneous Biopsy         | Primary Tumor    |
|                         | 1183.001| 57                       | F   | III   | No                                       | No                                           | Percutaneous Biopsy         | Primary Tumor    |
|                         | 1195.001*| 74                       | F   | II    | No                                       | No                                           | Percutaneous Biopsy         | Primary Tumor    |
|                         | 1227.001| 39                       | M   | IV    | No                                       | No                                           | Percutaneous Biopsy         | Primary Tumor    |
|                         | 1235.001| 60                       | F   | III   | No                                       | No                                           | Percutaneous Biopsy         | Primary Tumor    |
|                         | 1337.001| 62                       | F   | III   | No                                       | No                                           | Percutaneous Biopsy         | Primary Tumor    |
|                         | PCSI_0017| 53                       | F   | III   | GC                                       | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | PCSI_0048| 76                       | M   | II    | No                                       | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | PCSI_0075| 75                       | M   | IIA   | No                                       | No                                           | Distal pancreatectomy       | Primary Tumor    |
|                         | PCSI_0142| 43                       | M   | IIIB  | No                                       | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | PCSI_0176| 56                       | F   | II    | GC                                       | Yes                                          | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | PCSI_0218| 50                       | M   | IIIB  | No                                       | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | PCSI_0472| 75                       | M   | IA    | No                                       | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | PCSI_0477| 63                       | M   | II    | No                                       | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | PCSI_0492| 66                       | F   | IIIB  | No                                       | No                                           | Pancreaticoduodenectomy     | Primary Tumor    |
|                         | 303.001| 56                       | M   | III   | FFX                                      | Yes                                          | Total pancreatectomy + PV resection + right hemicolectomy | Primary Tumor    |
|                         | 1099.001| 52                       | F   | III   | FFX                                      | Yes                                          | Surgical exploration/metastatic peritoneal biopsy | Primary Peritoneal Metastasis |
|                         | 750.001| 55                       | M   | II    | FFX                                      | Yes                                          | Subtotal pancreatectomy + splenectomy | Primary Tumor    |

*Treated concurrently for lung cancer and excluded from the overall survival analysis.
RFA, radiofrequency ablation; PV, portal vein; SMA, superior mesenteric artery.
FFX, FOLFRINOX; GC, gemcitabine/cisplatin.
leads to increased levels of neoantigens and tumor immunogenicity, the immune cell landscape of HR-d PDAC should also be distinguishable from the typical immune cold PDAC microenvironment. To this end, our results demonstrating elevated levels of intra-tumoral CD8+ T-cells in HR-d compared to HR/MMR-intact PDAC suggest that HR-d PDAC harbors a microenvironment with an inherent anti-tumor immune response. In support of the hypothesis that the genomic instability of HR-d tumors results in increased immunogenicity, a retrospective study of melanoma patients treated with ICI therapy found that tumors that regressed were enriched for BRCA2 loss of function mutations and harbored a higher TMB (37).
We also evaluated the tumor microenvironment topography of FOXP3+ Tregs and CD68+ TAMs, since their immunosuppressive properties counterpoise the anti-tumor effect of cytotoxic CD8+ T-lymphocytes (38, 39). Tregs and TAMs may lower ICI efficacy and contribute to ICI resistance (40). Moreover, elevated levels of tumor infiltrating Tregs and TAMs correlate with poor outcomes in PDAC and other malignancies (31). We detected Tregs and TAMs in both HR-d and HR/MMR-intact cases, but we only observed a difference in the intra-tumoral density of Tregs between the two groups. The increase in intra-tumoral Tregs suggests an immunosuppressive counterbalance response to the anti-tumoral effect of the CD8+ T-cell infiltration. The MMR-d case with a durable response to pembrolizumab exhibited comparable levels of Tregs and TAMs in its intra-tumoral, peri-tumoral and stromal regions.

HR-d cases had a significantly higher CD8+:FOXP3+ ratio compared to HR/MMR-intact cases. The CD8+:FOXP3+ ratio may be a more functional measure of anti-tumor immunity and a better indicator of ICI responsiveness compared to CD8+ and FOXP3+ measurements alone (41). As the proportion of CD8+ to FOXP3+ rises, escape of CD8+ cytotoxic activity is facilitated with the dilution of Tregs and their inhibitory effects. The resultant milieu may also enhance the efficacy of ICI therapies. However, the CD8+:FOXP3+ threshold that signifies ICI responsiveness remains to be defined.

Although Tregs are considered to be pro-tumoral and have been associated with poor clinical outcomes in PDAC (31, 41), their role may be more complex. Depletion of Tregs in a transgenic mouse model of exocrine pancreatic cancer did not relieve the Treg immunosuppressive effects, but instead led to tumor progression (42). TAMs are also peculiar immune cells that exhibit functional plasticity with their phenotypic polarization governed by environmental signals (40). The functional continuum of TAMs ranges from pro-tumor to anti-tumor activity. In PDAC, immunosuppressive polarization of TAMs has been proposed, which is likely promoted by the predominantly hypoxic PDAC microenvironment (39). Although the exact contributions of Tregs and TAMs to the pro-tumor versus anti-tumor counterforces in the PDAC microenvironment are not fully understood, their roles are likely largely immunosuppressive considering their abundance across all PDAC and the generally immune cold PDAC microenvironment (31, 40, 43). Moreover, their prevalence in MMR-d may underlie the lower efficacy of ICIs in MMR-d...
PDAC compared to other MMR-d cancers (44). Therefore, ICI therapies PDAC subtypes with immunogenicity, including MMR-d, may be enhanced with the addition of agents that target suppressive immune cells such as TAMs (45).

Expression of PD-L1 by tumor or tumor-infiltrating immune cells has emerged as a clinical biomarker for anti-tumor immunity that may be enhanced with ICI therapy (23, 46). However, PD-L1 status is not a predictive biomarker of ICI sensitivity across all cancer types. Indeed, Davis et al. reviewed 45 FDA ICI approvals and found that PD-L1 was only predictive in 29% of cases, with the remainder either not tested or not predictive (47). Despite these limitations, in addition to MMR testing, PD-L1 expression currently remains the only feasible clinical assay for ICI treatment selection across cancer types (30). As such, we compared PD-L1 positivity by IHC in HR-d versus HR/MMR-intact PDAC, and found increased PD-L1 immunostaining in the HR-d group. Since guidelines for interpreting PD-L1 staining in PDAC have not been established, we applied the Combined Positive Score (CPS) that is recognized as a clinically relevant scoring method of PD-L1 positivity in solid tumors (23, 48). Although tumors that do not meet the CPS positivity threshold of ≥1 may respond to ICIs, tumors that reach the CPS cutoff have a higher likelihood of responding effectively to anti-PD-1 therapy. Strikingly, 6 of 25 HR-d cases and the MMR-d case met the ≥1 CPS threshold, while none of the 163 evaluable HR/MMR-intact cases reached the benchmark. These observations support a role for anti-PD-1 therapy in HR-d PDAC. Moreover, considering the heterogeneity of treatment responses to platinum and PARP inhibitors across HR-d PDAC (14, 17), sensitivity to anti-PD-1 may also be variable in HR-d PDAC and may be correlated with PD-L1 positivity. Finally, a limitation of this research registry-based study is the inclusion of cases that were treatment naive at the time of tissue acquisition as well as cases following pre-treatment with chemoradiation that may have altered their tumor microenvironment (49).

In summary, we demonstrate that HR-d PDAC exhibits a distinguishable tumor microenvironment with enhanced immunogenicity and PD-L1 positivity compared to HR/MMR-intact PDAC. These findings provide immunohistochemical correlation of the previously reported genomic and transcriptomic results classifying HR-d PDAC as a molecular subtype with inherent immunogenicity, and provide motivation for clinical trials to evaluate the efficacy of immunotherapy regimens in HR-d PDAC.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The study was conducted in accordance with the principles of the Declaration of Helsinki. The McGill University and the McGill University Health Centre (MUHC) Institutional Review Boards (A02-M118-11A, #2018-3171, #2018-4139) approved the QPCS study, and the Institutional Review Board of the University Health Network (#15-9596) provided approval for the PanCuRx case series. All patients provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

BG: Conceptualization, Methodology, Software, Validation, Formal Analysis, Investigation, Data Curation, Writing – Original Draft, Review & Editing, Visualization. YW: Conceptualization, Methodology, Validation, Investigation, Data Curation, Writing – Original Draft, Writing – Review & Editing. AT: Methodology, Formal Analysis, Investigation, Software, Writing – Review & Editing. AP: Software, Data Curation, Writing – Review & Editing. JR: Software, Writing – Review & Editing. CD: Data Curation, Resources, Writing – Review & Editing. GBourd: Data Curation, Resources, Writing – Review & Editing. GO’K: Methodology, Validation, Resources, Writing – Review & Editing. SF: Methodology, Validation, Resources, Writing – Review & Editing. AO: Resources, Validation, Writing – Review & Editing. M-CG: Resources, Validation, Writing – Review & Editing. Z-HG: Resources, Validation, Writing – Review & Editing. AD: Methodology, Validation, Resources, Writing – Review & Editing. AE: Methodology, Validation, Resources, Writing – Review & Editing. FD: Resources, Validation, Writing – Review & Editing. CM-K: Resources, Validation, Writing – Review & Editing. P-OF: Resources, Validation, Writing – Review & Editing. JWG: Resources, Validation, Writing – Review & Editing. M-CG: Resources, Validation, Writing – Review & Editing. Z-HG: Resources, Validation, Writing – Review & Editing. GZ: Conceptualization, Resources, Writing – Original Draft, Review & Editing. Supervision, Project Administration.

FUNDING

This work was supported by the Terry Fox Research Institute (project no. 1078), the Pancreatic Cancer Canada Foundation, the Quebec Cancer Consortium with funding from the Ministère de l’Économie et de l’Innovation du Québec through the Fonds d’accélération des collaborations en santé, and the PanCuRx Translational Research Initiative with funding by the Government of Ontario through the Ontario Institute for Cancer Research. Germline testing for the QPCS case series was partially subsidized by Invitae (San Francisco, CA). BGo was supported by a Canderel Graduate Studentship and the Cedars Cancer Institute Fellowship. YW was supported by a Vanier Canada Graduate Scholarship, the Fonds de recherche du

Frontiers in Oncology | www.frontiersin.org 10  April 2022 | Volume 12 | Article 860767
Québec–Santé/Ministère de la Santé et des Services sociaux training program, and the McGill University Surgical-Scientist Program. JR was supported by the Fonds de recherche du Québec–Santé/Ministère de la Santé et des Services sociaux training program and the Hilton J. McKeown Stipend from McGill University. GZ is a clinical research scholar of the Fonds de recherche du Québec–Santé and recipient of the Michal & Renata Hornstein Career Award from McGill University.

ACKNOWLEDGMENTS

We would also like to acknowledge Cleber Moraes and Dongmei Zuo for their technical assistance.

REFERENCES

1. Ferlay J EM, Lam F, Colomber M, Mery L, Pıneros M, Znaor A, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, (2020). Available at: https://gco.iarc.fr/fr/today.

2. Wang Y, Lakoma A, Zogopoulos G. Building Towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes (2020) 11(9):1098. doi: 10.3390/genes11091098

3. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant Chemotherapy With Gemcitabine and Long-Term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial. JAMA (2013) 310(14):1473–81. doi: 10.1001/jama.2013.279201

4. Neoptolemos JP, Palmer DH, Gallinger S, Gagnon J, Fong Y, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA (2018) 319(23):2401–9. doi: 10.1001/jama.2018.6228

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.860767/full#supplementary-material

Supplementary Figure 1 | Kaplan-Meier survival curves for the HR-d and HR- MMR-intact groups.

Supplementary Figure 2 | MMR-d PDAC. (A) IHC of QPCS case 750.001 showing intact nuclear MSH2 and absent nuclear MSH6 staining (red arrow) with intact stromal MSH2 and MSH6 staining (blue arrow) to indicate MMR-d. (B) Computed tomography showing mesenteric recurrence (orange arrow) following surgical resection of the primary. (C) Computed tomography following 18 months of pembrolizumab treatment showing a decrease in the mesenteric recurrence (orange arrow), indicating partial treatment response.

13. Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, et al. Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. JCO Precis Oncol (2018) 2(1):1–16. doi: 10.1200/PO.17.00098

14. Golan T, O’Kane GM, Denroche RE, Raitses-Gurevich M, Grant RC, Holter S, et al. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Gastroenterology (2021) 160:2119–32. doi: 10.1053/j.gastro.2021.01.220

15. Lord CJ, Ashworth A. The DNA Damage Response and Cancer Therapy. Nature (2012) 481(7381):287–94. doi: 10.1038/nature10760

16. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of Somatic Mutations in 560 Breast Cancer Whole-Genome Sequences. Nature (2015) 534(7605):47–54. doi: 10.1038/nature16766

17. Wang Y, Park JYP, Pacis A, Denroche RE, Jang GH, Zhang A, et al. A Preclinical Trial and Moleculately Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-Deficient Pancreatic Cancer. Clin Cancer Res (2020) 26(20):5462–76. doi: 10.1158/1078-0432.CCR-20-1439

18. Maleki Vareki S. High and Low Mutational Burden Tumors Versus Immunologically Hot and Cold Tumors and Response to Immune Checkpoint Inhibitors. J Immunother Cancer (2018) 6(1):157. doi: 10.1186/s40425-018-0479-7

19. Grant RC, Denroche R, Jang GH, Nowak KM, Zhang A, Borgida A, et al. Clinical and Genomic Characterisation of Mismatch Repair Deficient Pancreatic Adenocarcinoma. Gut (2020) 70(7):1894–903. doi: 10.1136/gutjnl-2020-320730

20. Luchini C, Brosens LAA, Wood LD, Chatterjee D, Shin JJ, Sciammarella C, et al. Comprehensive Characterisation of Pancreatic Ductal Adenocarcinoma With Microsatellite Instability: Histology, Molecular Pathology and Clinical Implications. Gut (2021) 70(1):148–56. doi: 10.1136/gutjnl-2020-320726

21. Smith AL, Bascunana C, Hall A, Salmon A, Andrei AZ, Volenik A, et al. Establishing a Clinical-Based Pancreatic Cancer and Periampullary Tumour Research Registry in Quebec. Curr Oncol (2015) 22(2):113–21. doi: 10.3747/ co.22.2300

22. Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, et al. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol (2017) 3(6):774–83. doi: 10.1001/jamaoncol.2016.3916

23. Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. Arch Pathol Lab Med (2018) 142(3):330–7. doi: 10.5858/ arpa.2018-0043-OA

24. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol (2015) 1(1):23–32. doi: 10.1001/jamaoncol.2014.168

25. Wong C, Chen F, Alirezai N, Wang Y, Cuggia A, Borgida A, et al. A Region-Based Gene Association Study Combined With a Leave-One-Out Sensitivity
Analysis Identifies SMG1 as a Pancreatic Cancer Susceptibility Gene. *PloS Genet* (2019) 15(8):e1008344. doi: 10.1371/journal.pgen.1008344

26. Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a Predictor of BRCA1 and BRCA2 Deficiency Based on Mutational Signatures. *Nat Med* (2017) 23(4):517–25. doi: 10.1038/nm.4929

27. Golan T, Hammad P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med* (2019) 381(4):317–27. doi: 10.1056/NEJMoa1903387

28. O’Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Caspivatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. *J Clin Oncol* (2020) 38(13):1378–88. doi: 10.1200/JCO.19.02931

29. Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, et al. Mutations in BRCA1 and BRCA2 Differentially Affect the Tumor Microenvironment and Response to Checkpoint Blockade Immunotherapy. *Nat Cancer* (2021) 1(12):1188–203. doi: 10.1038/s43018-020-00139-8

30. Pardoll DM. The Blockade of Immune Checkpoints in Cancer Immunotherapy. *Nat Rev Cancer* (2012) 12(4):252–64. doi: 10.1038/nrc3239

31. Orhan A, Vogelsang RP, Andersen MB, Madsen MT, Hölmich ER, Raskov H, et al. The Prognostic Value of Tumour-Inferring Lymphocytes in Pancreatic Cancer: A Systematic Review and Meta-Analysis. *Eur J Cancer* (2020) 132:71–84. doi: 10.1016/j.ejca.2020.03.013

32. Ku BM, Kim Y, Lee KY, Lee KW, Makarova V, et al. Mutations of Immune Cell Types Support Distinct Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *Eur J Immunol* (2021) 51(4):956–64. doi: 10.1002/eji.202049896

33. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, et al. Comparison of Immune Infiltrates in Melanoma and Pancreatic Cancer Highlights VISTA as a Potential Target in Pancreatic Cancer. *Proc Natl Acad Sci* (2019) 116(5):1692–7. doi: 10.1073/pnas.1811076116

34. Romero JM, Grünwald B, Jang G-H, Bavi PP, Jhaevener A, Masoomian M, et al. A Four-Chemokine Signature Is Associated With a T-Cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. *Clin Cancer Res* (2020) 26(8):1997–2010. doi: 10.1158/1078-0432.CCR-19-2803

35. Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, et al. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. *Gastroenterology* (2018) 155(6):1999–2013.e3. doi: 10.1015/j.gastro.2018.08.033

36. Fraune C, Burandt E, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, et al. MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated With High Density of CD8-Positive Lymphocytes. *Ann Surg Oncol* (2020) 27(10):3997–4006. doi: 10.1245/s10434-020-00829-v

37. Hugo W, Zaretzky JM, Sun L, Song C, Moreno BH, Hu-Lieskovski S, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell* (2016) 165(1):35–44. doi: 10.1016/j.cell.2016.02.065

38. Sahin IH, Askani G, Hu ZL, O’Reilly EM. Immunotherapy in Pancreatic Ductal Adenocarcinoma: An Emerging Entity? *Ann Oncol* (2017) 28(12):2950–61. doi: 10.1093/annonc/mdx503

39. Lin Y, Xu J, Lan H. Tumor-Associated Macrophages in Tumor Metastasis: Biological Roles and Clinical Therapeutic Applications. *J Hematol Oncol* (2019) 12(1):76. doi: 10.1186/s13045-019-0760-3

40. Fares CM, Allen EMV, Drake CG, Allison JP, Hu-Lieskovski S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? *Am Soc Clin Oncol Educ Book* (2019) 39:147–64. doi: 10.1200/EDBK_240837

41. Kim H, Kwon HJ, Han YB, Park SY, Kim ES, Kim SH, et al. Increased CD3+ T Cells With a Low FOXP3+/CD8+ T Cell Ratio Can Predict Anti-PD-1 Therapeutic Response in Non-Small Cell Lung Cancer Patients. *Mod Pathol* (2019) 32(3):367–75. doi: 10.1038/s41379-018-0142-3

42. Zhang Y, Lazarus J, Steele NG, Yan W, Lee H-J, Nwosu ZC, et al. Regulatory T-Cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis. *Cancer Discovery* (2020) 10(3):422–39. doi: 10.1158/2159-8290.CD-19-0958

43. Saleh R, Elkord E. FoxP3+ T Regulatory Cells in Cancer: Prognostic Biomarkers and Therapeutic Targets. *Cancer Lett* (2020) 490:74–85. doi: 10.1016/j.canlet.2020.07.022

44. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol* (2020) 38(1):1–10. doi: 10.1200/JCO.19.02105

45. Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-Associated Macrophages: Recent Insights and Therapies. *Front Oncol* (2020) 10:188. doi: 10.3389/fonc.2020.00188

46. Gibney GT, Weiner LM, Atkins MB. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. *Lancet Oncol* (2016) 17(12):e542–e51. doi: 10.1016/S1470-2045(16)30465-5

47. Davis AA, Patel VG. The Role of PD-L1 Expression as a Predictive Biomarker: An Analysis of All US Food and Drug Administration (FDA) Approvals of Immune Checkpoint Inhibitors. *J Immunother Cancer* (2019) 7(1):278. doi: 10.1186/s40425-019-0768-9

48. Emancipator K. Keytruda and PD-L1: A Real-World Example of Co-Development of a Drug With a Predictive Biomarker. *AAPS J* (2020) 23(1):5. doi: 10.1208/s12248-020-00525-1

49. Michelakos T, Cai L, Villani V, Sabbatino F, Kontos F, Fernandez-Del Castillo C, et al. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. *J Natl Cancer Inst* (2021) 113(2):182–91. doi: 10.1093/jnci/djaa0673